Skip to main content
. 2013 Jul 5;27(4):235–242. doi: 10.3341/kjo.2013.27.4.235

Table 1.

Baseline characteristics of patients receiving a bevacizumab or ranibizumab injection for corneal neovascularization

graphic file with name kjo-27-235-i001.jpg